Company news
Lexaria Bioscience Corp. news in 2025
Lexaria Bioscience Corp.'s news releases, calls and decks from 2025, newest first.
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
December 30, 2025
Lexaria Releases Additional Results From Its Successful Phase 1b Study GLP-1-H24-4
December 29, 2025
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
December 23, 2025
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
November 12, 2025
Lexaria Bioscience Corp. Provides Strategic Update
October 9, 2025
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 29, 2025
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 26, 2025
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
August 27, 2025
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
August 14, 2025
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
August 6, 2025
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
July 28, 2025
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study
July 27, 2025
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
July 23, 2025
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
June 22, 2025
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
June 11, 2025
Lexaria Attending BIO International Convention
June 5, 2025
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
May 12, 2025
Lexaria Provides Update on Material Transfer Agreement With Pharmaceutical Company
May 11, 2025
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
April 28, 2025
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 3, 2025
Lexaria Updates Its Ongoing Human Study GLP-1-H24-4
April 2, 2025
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 2, 2025
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
February 24, 2025
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
February 20, 2025
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
February 10, 2025
Lexaria Biodistribution Study for DehydraTECH GLP-1 is Underway
February 5, 2025
Lexaria Releases Annual Letter From the CEO
January 29, 2025
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
January 14, 2025
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
January 14, 2025
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half With Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
January 13, 2025